Novo Nordisk is also pairing the long-acting insulin with its once-weekly GLP-1 agonist semaglutide in the COMBINE trials programme, which is due to complete in 2024, is also working on a glucose ...
Researchers concluded that it’s tied to glucose fluctuations, which can be more dramatic for those with T1D and on insulin than others who may not use insulin to manage their condition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback